Literature DB >> 11479173

Why is erythropoietin made in the kidney? The kidney functions as a critmeter.

S Donnelly1.   

Abstract

Erythropoietin is distinct among the hematopoietic growth factors because it is produced primarily in the kidneys rather than the bone marrow. The kidney functions as a critmeter in that it senses oxygen tension and extracellular volume. By regulating red cell mass through erythropoietin and plasma volume through excretion of salt and water, the kidney sets the hematocrit at a normal value of 45%. This is not a random number, but a value that maximizes oxygen delivery to peripheral tissues. The ability of the kidney to coordinate these two volumes to generate a hematocrit of 45% establishes it as the logical site for erythropoietin production. The kidney has the unique ability to translate a measure of plasma volume as tissue oxygen pressure required to regulate erythropoietin production. I hypothesize that the critmeter is a functional unit that regulates the hematocrit. The critmeter is found at the tip of the juxtamedullary region of the cortical labyrinth in the kidney, where erythropoietin is made physiologically. Renal vasculature and nephron segment heterogeneity in sodium reabsorption generate the marginal tissue oxygen pressure required to trigger the production of erythropoietin. The balance of the oxygen consumption for sodium reabsorption and the oxygen delivery to the proximal tubule is reflected by the tissue oxygen pressure that determines red blood cell mass adjusted to plasma volume. Factors that affect blood supply and sodium reabsorption in a discordant manner may modulate the critmeter (eg, angiotensin II). Examples of clinical disorders caused by dysfunction or resetting of the critmeter are described.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11479173     DOI: 10.1053/ajkd.2001.26111

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  21 in total

1.  Erythropoietin and blood doping.

Authors:  N Robinson; S Giraud; C Saudan; N Baume; L Avois; P Mangin; M Saugy
Journal:  Br J Sports Med       Date:  2006-07       Impact factor: 13.800

2.  Modelling the relationships between haemoglobin oxygen affinity and the oxygen cascade in humans.

Authors:  John R A Shepherd; Paolo B Dominelli; Tuhin K Roy; Timothy W Secomb; James D Hoyer; Jennifer L Oliveira; Michael J Joyner
Journal:  J Physiol       Date:  2019-07-25       Impact factor: 5.182

Review 3.  Circadian rhythms: from basic mechanisms to the intensive care unit.

Authors:  Ming-Cheng Chan; Peter M Spieth; Kieran Quinn; Matteo Parotto; Haibo Zhang; Arthur S Slutsky
Journal:  Crit Care Med       Date:  2012-01       Impact factor: 7.598

Review 4.  Management of anemia with erythropoietic-stimulating agents in children with chronic kidney disease.

Authors:  Bradley A Warady; Douglas M Silverstein
Journal:  Pediatr Nephrol       Date:  2013-09-05       Impact factor: 3.714

Review 5.  Erythropoietin, a multifaceted protein with innate and adaptive immune modulatory activity.

Authors:  Chiara Cantarelli; Andrea Angeletti; Paolo Cravedi
Journal:  Am J Transplant       Date:  2019-04-25       Impact factor: 8.086

Review 6.  Anemia in chronic kidney disease.

Authors:  Meredith A Atkinson; Bradley A Warady
Journal:  Pediatr Nephrol       Date:  2017-04-15       Impact factor: 3.714

7.  Effects of recombinant human erythropoietin on platelet activation in acute myocardial infarction: results of a double-blind, placebo-controlled, randomized trial.

Authors:  Yi-Da Tang; Faisal Hasan; Frank J Giordano; Stephen Pfau; Henry M Rinder; Stuart D Katz
Journal:  Am Heart J       Date:  2009-12       Impact factor: 4.749

8.  Hemoglobin decline in children with chronic kidney disease: baseline results from the chronic kidney disease in children prospective cohort study.

Authors:  Jeffrey J Fadrowski; Christopher B Pierce; Stephen R Cole; Marva Moxey-Mims; Bradley A Warady; Susan L Furth
Journal:  Clin J Am Soc Nephrol       Date:  2008-01-30       Impact factor: 8.237

9.  Low total haemoglobin mass, blood volume and aerobic capacity in men with type 1 diabetes.

Authors:  Anne S Koponen; Juha E Peltonen; Marja K Päivinen; Jyrki M Aho; Harriet J Hägglund; Arja L Uusitalo; Harri J Lindholm; Heikki O Tikkanen
Journal:  Eur J Appl Physiol       Date:  2012-11-06       Impact factor: 3.078

10.  Post-renal transplantation anemia at 12 months: prevalence, risk factors, and impact on clinical outcomes.

Authors:  Zhongli Huang; Turun Song; Lei Fu; Zhengsheng Rao; Dongyang Zeng; Yang Qiu; Xianding Wang; Libo Xie; Qiang Wei; Li Wang; Tao Lin
Journal:  Int Urol Nephrol       Date:  2015-08-06       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.